Skip to main content
Top
Published in: Clinical Rheumatology 5/2010

01-05-2010 | Original Article

Influences of anti-tumour necrosis factor agents on postoperative recovery in patients with rheumatoid arthritis

Authors: Yuji Hirano, Toshihisa Kojima, Yasuhide Kanayama, Tomone Shioura, Masatoshi Hayashi, Daihei Kida, Atsushi Kaneko, Yoshito Eto, Naoki Ishiguro

Published in: Clinical Rheumatology | Issue 5/2010

Login to get access

Abstract

The aim of this study is to investigate the influences of the anti-tumour necrosis factor (TNF) agents infliximab and etanercept on the postoperative recovery of patients with rheumatoid arthritis (RA). We also investigated the effects of biologics on wound healing. Patients with RA were split into a TNF group (n = 39) that underwent 39 operations and were treated with anti-TNF agents, and a non-TNF group (n = 74) that underwent 74 operations and were treated only with conventional disease-modifying antirheumatic drugs. Operations included ankle arthrodesis and total arthroplasty of the hip, knee, elbow, shoulder and ankle. Adverse events (AEs) of surgical wounds, time for complete wound healing, febrile period after operation and recovery parameters after operation (%recovery of haemoglobin (Hb), total protein and albumin at 4 weeks after operation compared with pre-operation levels) were investigated. AEs of surgical wounds occurred in two operations (5.1%) in the TNF group and in five operations (6.8%) in the non-TNF group, but this difference was not statistically significant. There were also no significant differences in the time for complete wound healing and in the length of the febrile period between the two groups. Percentage recovery of Hb was significantly better in the TNF group than in the non-TNF group (96.3% vs. 90.1%, respectively; p < 0.05). These results suggest that the use of anti-TNF agents does not cause specific AEs on surgical wounds after elective orthopaedic operations in RA patients and might improve the percentage recovery of Hb due to its prompt anti-TNF effects.
Literature
1.
go back to reference Maini R, St Clair EW, Breedveld F, Furst D, Kalden J, Weisman M et al (1999) Infliximab (chimeric anti-tumor necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotorexate: a randomized phase III trial. Lancet 354:1932–1939CrossRefPubMed Maini R, St Clair EW, Breedveld F, Furst D, Kalden J, Weisman M et al (1999) Infliximab (chimeric anti-tumor necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotorexate: a randomized phase III trial. Lancet 354:1932–1939CrossRefPubMed
2.
go back to reference Weinblatt ME, Kremer JM, Bankhurst AD, Bulpitt KJ, Fleischmann RM, Fox RI et al (1999) A trial of etanercept, a recombinant human tumor necrosis factor: Fc fusion protein in patients with rheumatoid arthritis receiving methotrexate. N Eng J Med 340:253–259CrossRef Weinblatt ME, Kremer JM, Bankhurst AD, Bulpitt KJ, Fleischmann RM, Fox RI et al (1999) A trial of etanercept, a recombinant human tumor necrosis factor: Fc fusion protein in patients with rheumatoid arthritis receiving methotrexate. N Eng J Med 340:253–259CrossRef
3.
go back to reference Choy EH, Panayi GS (2001) Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med 344:907–916CrossRefPubMed Choy EH, Panayi GS (2001) Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med 344:907–916CrossRefPubMed
4.
go back to reference Mooney DP, O’Reilly M, Gamelli RL (1990) Tumor necrosis factor and wound healing. Ann Surg 211:124–129CrossRefPubMed Mooney DP, O’Reilly M, Gamelli RL (1990) Tumor necrosis factor and wound healing. Ann Surg 211:124–129CrossRefPubMed
5.
go back to reference Salomon GD, Kasid A, Cromack DT, Director E, Talbot TL, Sank A et al (1991) The local effects of cachectin/tumor necrosis factor on wound healing. Ann Surg 214:175–180CrossRefPubMed Salomon GD, Kasid A, Cromack DT, Director E, Talbot TL, Sank A et al (1991) The local effects of cachectin/tumor necrosis factor on wound healing. Ann Surg 214:175–180CrossRefPubMed
6.
go back to reference Mori R, Kondo T, Ohshima T, Ishida Y, Mukaida N (2002) Accelerated wound healing in tumor necrosis factor receptor p55-deficient mice with reduced leukocyte infiltration. FASEB J 16:963–974CrossRefPubMed Mori R, Kondo T, Ohshima T, Ishida Y, Mukaida N (2002) Accelerated wound healing in tumor necrosis factor receptor p55-deficient mice with reduced leukocyte infiltration. FASEB J 16:963–974CrossRefPubMed
7.
go back to reference Takashima K, Tateda K, Matsumoto T, Iizawa Y, Nakao M, Yamaguchi K (1997) Role of tumor necrosis factor alpha in pathogenesis of pneumonia in mice. Infect Innun 65:257–260 Takashima K, Tateda K, Matsumoto T, Iizawa Y, Nakao M, Yamaguchi K (1997) Role of tumor necrosis factor alpha in pathogenesis of pneumonia in mice. Infect Innun 65:257–260
8.
go back to reference Rothe J, Lesslauer W, Lotcher H, Lang Y, Koebel P, Kontgen F (1993) Mice lacking the tumor necrosis factor receptor 1 are resistant to TNF-mediated toxicity but highly susceptible to infection by Listeria monocytegenes. Nature 364:798–802CrossRefPubMed Rothe J, Lesslauer W, Lotcher H, Lang Y, Koebel P, Kontgen F (1993) Mice lacking the tumor necrosis factor receptor 1 are resistant to TNF-mediated toxicity but highly susceptible to infection by Listeria monocytegenes. Nature 364:798–802CrossRefPubMed
9.
go back to reference Tite JP, Dougan G, Chatfield SN (1991) The involvement of tumor necrosis factor in immunity to Salmonella infection. J Immunol 147:3161–3164PubMed Tite JP, Dougan G, Chatfield SN (1991) The involvement of tumor necrosis factor in immunity to Salmonella infection. J Immunol 147:3161–3164PubMed
10.
go back to reference Seo SH, Webster RG (2002) Tumor necrosis factor alpha exerts powerful anti-influenza virus effects in lung epithelial cells. J Virol 76:1071–1076PubMed Seo SH, Webster RG (2002) Tumor necrosis factor alpha exerts powerful anti-influenza virus effects in lung epithelial cells. J Virol 76:1071–1076PubMed
11.
go back to reference Furst DE, Wallis R, Broder M, Beenhouwer DO (2006) Tumor necrosis factor antagonists: different kinetics and/or mechanisms of action may explain differences in the risk for developing granulomatous infection. Semin Arthritis Rheum 36:159–167CrossRefPubMed Furst DE, Wallis R, Broder M, Beenhouwer DO (2006) Tumor necrosis factor antagonists: different kinetics and/or mechanisms of action may explain differences in the risk for developing granulomatous infection. Semin Arthritis Rheum 36:159–167CrossRefPubMed
12.
go back to reference den Broeder AA, Creemers MCW, Fransen J, de Jong E, de Rooij DR, Wymenga A et al (2007) Risk factors for surgical site infections and other complications in elective surgery in patients with rheumatoid arthritis with special attention for anti-tumor necrosis factor: a large retrospective study. J Rheumatol 34:689–695 den Broeder AA, Creemers MCW, Fransen J, de Jong E, de Rooij DR, Wymenga A et al (2007) Risk factors for surgical site infections and other complications in elective surgery in patients with rheumatoid arthritis with special attention for anti-tumor necrosis factor: a large retrospective study. J Rheumatol 34:689–695
13.
go back to reference Means RT Jr (2003) Recent development in the anemia of chronic disease. Curr Hematol Rep 2:116–121PubMed Means RT Jr (2003) Recent development in the anemia of chronic disease. Curr Hematol Rep 2:116–121PubMed
14.
go back to reference Jongen-Lavrencic M, Peeters HR, Wognum A, Vreugdenhil G, Breedveld FC, Swaak AJ (1997) Elevated levels of inflammatory cytokines in bone marrow of patients with rheumatoid arthritis and anemia of chronic disease. J Rheumatol 24:1504–1509PubMed Jongen-Lavrencic M, Peeters HR, Wognum A, Vreugdenhil G, Breedveld FC, Swaak AJ (1997) Elevated levels of inflammatory cytokines in bone marrow of patients with rheumatoid arthritis and anemia of chronic disease. J Rheumatol 24:1504–1509PubMed
15.
go back to reference Papadaki HA, Krikikos HD, Valatas V, Boumpas DT, Eliopoulos GD (2002) Anemia of chronic disease in rheumatoid arthritis is associated with increased apoptosis of bone marrow erythroid cells: improving following anti-tumor necrosis factor-alpha antibody therapy. Blood 100:474–482CrossRefPubMed Papadaki HA, Krikikos HD, Valatas V, Boumpas DT, Eliopoulos GD (2002) Anemia of chronic disease in rheumatoid arthritis is associated with increased apoptosis of bone marrow erythroid cells: improving following anti-tumor necrosis factor-alpha antibody therapy. Blood 100:474–482CrossRefPubMed
16.
go back to reference Saag KG, Teng GG, Patkar NM, Anuntiyo J, Finney C, Curtis JR et al (2008) American college of rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum 15:762–784CrossRef Saag KG, Teng GG, Patkar NM, Anuntiyo J, Finney C, Curtis JR et al (2008) American college of rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum 15:762–784CrossRef
17.
go back to reference Koike R, Takeuchi T, Eguchi K, Miyasaka N (2007) Update on the Japanese guidelines for the use of infliximab and etanercept in rheumatoid arthritis. Mod Rheumatol 17:451–458CrossRefPubMed Koike R, Takeuchi T, Eguchi K, Miyasaka N (2007) Update on the Japanese guidelines for the use of infliximab and etanercept in rheumatoid arthritis. Mod Rheumatol 17:451–458CrossRefPubMed
18.
go back to reference Talwalkar SC, Grennan DM, Gray J, Johnson P, Hayton MJ (2005) Tumor necrosis factorα antagonists and early postoperative complications in patients with inflammatory joint disease undergoing elective orthopaedic surgery. Ann Rheum Dis 64:650–651CrossRefPubMed Talwalkar SC, Grennan DM, Gray J, Johnson P, Hayton MJ (2005) Tumor necrosis factorα antagonists and early postoperative complications in patients with inflammatory joint disease undergoing elective orthopaedic surgery. Ann Rheum Dis 64:650–651CrossRefPubMed
19.
go back to reference Bibbo C, Goldberg JW (2004) Infectious and healing complications after elective orthopaedic foot and ankle surgery during tumor necrosis factor-alpha inhibition therapy. Foot Ankle Int 25:331–335PubMed Bibbo C, Goldberg JW (2004) Infectious and healing complications after elective orthopaedic foot and ankle surgery during tumor necrosis factor-alpha inhibition therapy. Foot Ankle Int 25:331–335PubMed
20.
go back to reference Wendling D, Balblanc JC, Brousse A, Lohse A, Lehuede G, Garbuio P et al (2005) Surgery in patients receiving anti-tumour necrosis factor alpha treatment in rheumatoid arthritis: an observational study on 50 surgical procedures. Ann Rheum Dis 64:1378–1379CrossRefPubMed Wendling D, Balblanc JC, Brousse A, Lohse A, Lehuede G, Garbuio P et al (2005) Surgery in patients receiving anti-tumour necrosis factor alpha treatment in rheumatoid arthritis: an observational study on 50 surgical procedures. Ann Rheum Dis 64:1378–1379CrossRefPubMed
21.
go back to reference Giles JT, Bartlett SJ, Gelber AC, Nanda S, Fontaine K, Ruffing V et al (2006) Tumor necrosis factor inhibitor therapy and risk of serious postoperative orthopedic infection in rheumatoid arthritis. Arthritis Rheum 55:333–337CrossRefPubMed Giles JT, Bartlett SJ, Gelber AC, Nanda S, Fontaine K, Ruffing V et al (2006) Tumor necrosis factor inhibitor therapy and risk of serious postoperative orthopedic infection in rheumatoid arthritis. Arthritis Rheum 55:333–337CrossRefPubMed
Metadata
Title
Influences of anti-tumour necrosis factor agents on postoperative recovery in patients with rheumatoid arthritis
Authors
Yuji Hirano
Toshihisa Kojima
Yasuhide Kanayama
Tomone Shioura
Masatoshi Hayashi
Daihei Kida
Atsushi Kaneko
Yoshito Eto
Naoki Ishiguro
Publication date
01-05-2010
Publisher
Springer-Verlag
Published in
Clinical Rheumatology / Issue 5/2010
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-009-1346-1

Other articles of this Issue 5/2010

Clinical Rheumatology 5/2010 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.